Bcakground

Int erf ero n bet a (I F N - bet a ) , also known as fibroblast IF N, is a se creted, approximately 22 kDa member of the type I interferon family of molecules (1 ). Mature human IFN-beta shares 47% and 46% amino acid sequence identity with the mouse and rat proteins, respectively. Fibroblasts are the major producers of IF N-be ta, but it can als o be produced by dendritic cells, macrophages, and endothelial cells in res pons e to pathogen exposur e (2). It is trans -criptionally regulated by TRAF3, IRF3, IRF7, and NF-kappa B (3). Following secretion, IFN-beta signals through the heterodimeric IFN-alpha / beta Receptor and activates the JAK/STAT signaling pathway (4-7). IFN-beta -deficient mice show increased susceptibility to experimental autoimmune encephalomyelitis ( E AE ), a disease model of human multiple s clerosis (M S ) (8). Furth ermore, IF N-be ta has been shown to s uppress the Th 17 cell respons e in both MS and EAE and has commonly been used as a treatment for MS (9-13).

Reference

1. González-Navajas, J.M. et al. (2012) Nat. Rev. Immunol. 12:125.

2. Reder, A.T. and X. Feng (2013) Front. Immunol. 4:281.

3. Schafer, S.L. et al. (1998) J. Biol. Chem. 273:2714.

4. Honda, K. et al. (2006) Nat. Rev. Immunol. 6:644.

5. Platanias, L.C. (2005) Nat. Rev. Immunol. 5:375.

6. Fasler-Kan, E. et al. (1998) Eur. J. Biochem. 254:514.

7. Matikainen, S. et al. (1999) Blood 93:1980.

8. Teige, I. et al. (2003) J. Immunol. 170:4776.

9. Shinohara, M.L. et al. (2008) Immunity 29:68.

10.Guo, B. et al. (2008) J. Clin. Invest. 118:1680.

11.Ramgolam, V.S. and S. Markovic-Plese (2010) Endocr. Metab. Immune Disord. Drug Targets 10:161.

12. Martín-Saavedra, F.M. et al. (2008) Mol. Immunol. 45:4008.

13. Inoue M. and M.L. Shinohara (2013) Immunology 139:11.

Specifications

Synonyms	Fibroblast interferon; IFB; IFBIFNB; IFF; IFNB; IFNB1; IFNbeta; IFN-beta; interferon beta
Accession #	P01574
Source	Human embryonic kidney cell, HEK293-derived human IFN-beta protein
Predicted Moleucular weight	Met22-Asn187
Form/Structure	20.0 kDa

Components and Storage

Formulation	Solution protein
	Dissolved in sterile PBS buffer.
	This solution can be diluted into other aqueous buffers. Centrifuge the vial prior to opening.
Storage and Stability	Avoid repeated freeze-thaw cycles.
	It is recommended that the protein be aliquoted for optimal storage.
	12 months from date of receipt, -20 to -70 °C as supplied.
Shipping	Shipping with dry ice

Quality

Purity	> 95%, determined by SDS-PAGE
Endotoxin Stability	<0.010 EU per 1 ug of the protein by the LAL method
Shipping	Measured in anti- viral assa ys using HeLa humancervical epithelial carcinomacells infected with encephalomyocarditi
Shipping	(EMC) virus.The EC50 for this effect is 1-10 ng/mL.

SDS-PAGE

Bioactivity

Documents

Human IFNB